CareDx CEO Sells Shares in Planned Transaction
CareDx's CEO sold 17,683 shares in a planned move worth over $424,000.
Key Points
- CareDx CEO Hanna John Walter Jr. sold 17,683 shares for $24.03 each, totaling $424,922.49 on June 15, 2026.
- Shares of CareDx, Inc. (NasdaqGM: CDNA) are trading around $23.25 with a market cap of approximately $1.2 billion.
- BTIG and Wells Fargo analysts have maintained ratings on CDNA, with price targets ranging from $21 to $28.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hanna John Walter Jr., President and CEO of CareDx, Inc. (NasdaqGM: CDNA), recently sold 17,683 shares of the company. The transaction, which was planned, took place on June 15, 2026, at an average price of $24.03 per share, amounting to approximately $424,922.49.
Insider Buying and Selling at CareDx, Inc.
On June 15, 2026, CareDx's CEO Hanna John Walter Jr. executed a planned sale of 17,683 shares at $24.03 each, valued at $424,922.49. Other insiders, including Hannah Valantine, also sold shares on the same day. Meanwhile, Christine Cournoyer, Suresh Gunasekaran, and Fred Cohen each bought 9,795 shares on June 12, 2026, with no price disclosed.
Other Institutional Activity in CareDx
Several institutional investors have been active in CareDx recently. BlackRock, Inc. reduced its holdings by 128,313 shares, leaving it with 4,522,096 shares valued at $78.5 million. BAMCO Inc. added 181,229 shares, resulting in a total of 3,336,409 shares worth $57.9 million. State Street Corp increased its position by 22,633 shares to hold 2,760,385 shares valued at $47.9 million. ARK Investment Management LLC added 91,153 shares, bringing its total to 2,227,556 shares, valued at $38.7 million. Braidwell LP significantly increased its holdings by 587,926 shares, ending with 2,173,146 shares valued at $37.7 million.
CareDx, Inc. Stock Down 53.3%
CareDx, Inc. (NasdaqGM: CDNA) is currently trading around $23.25. The company has a market capitalization of approximately $1.2 billion and a forward P/E ratio of 20.5. Its stock has experienced a 52-week range between $10.96 and $24.85. The 50-day moving average is $21.09, while the 200-day moving average stands at $18.23. CareDx has a beta of 2.479, indicating higher volatility compared to the market.
$CDNA stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
CareDx reported revenues of $412.8 million, showing a growth of 39%. Despite this, the company posted a net margin of -1.98% and a return on equity of -2.37%, reflecting its current unprofitable status. The next earnings report is expected on August 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
1 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 149.6%. Revenue beat estimates by 10.8%.
-
Profit surprise
EBITDA missed by 9 percent. Operating income beat by 11 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise.
-
Earnings quality
Gross margin up 5.0 points. Operating margin up 17.3 points. Negative free cash flow.
Earnings Call Summary
The company reported strong first quarter results with $118 million in revenue, up 39 percent year over year, beating expectations by about $11 million. Testing services grew 48 percent and each test brought in $16.60 on average. Management announced two major moves: selling the Lab Products business to focus on testing services, and acquiring Navaris to expand into viral cancer testing where they can apply their expertise in repeat monitoring and workflow automation.
Guidance CareDx expects about $456 million in revenue for 2026, up 20 percent from 2025. They also expect adjusted EBITDA of about $50 million, up 58 percent. The company is selling off its Lab Products business for $170 million in cash and acquiring Navaris, which makes cancer tests for about $34 million in revenue last year.
Good report. The company beat and showed some forward improvement, with a few meaningful caveats.
Analysts Set New Price Targets
BTIG has maintained a 'buy' rating on CareDx with a price target of $28 as of April 29, 2026. Wells Fargo, on the other hand, maintained a 'hold' rating with a $21 target on February 25, 2026. The consensus among analysts is a 'buy' with a mean target price of $25.8, based on five opinions.
About CareDx
CareDx, Inc., based in Brisbane, California, operates in the healthcare sector, focusing on diagnostics and research. It provides solutions to improve outcomes for transplant patients and advance organ health. Their offerings include AlloSure Kidney and Heart, which are donor-derived cell-free DNA solutions for kidney and heart transplant patients, respectively. The company also provides a range of other products and services aimed at enhancing transplant patient management. Founded in 1998, CareDx is led by CEO Mr. John Walter Hanna Jr. and employs over 760 people.
Bottom Line
CareDx's CEO selling shares is a notable event, but it was a planned transaction, which often doesn't imply any negative sentiment. Investors keep an eye on such insider activities for insights into company dynamics. CareDx remains a significant player in the healthcare diagnostics field, with analysts showing varied opinions on its stock potential. As always, remember that insider transactions are disclosed after the fact and may not represent current insider sentiment.
Get CareDx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CDNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.